Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Nov 2, 2026

Maureen McBeth, Senior Manager of Clinical Research and Education at ImpediMed, discusses how sarcopenia, age-related muscle loss, significantly impacts the ability of cancer patients to tolerate treatment, yet has historically not been considered very relevant. ImpediMed has developed an FDA-cleared digital health...


Nov 2, 2026

Maureen McBeth, Senior Manager of Clinical Research and Education at ImpediMed, discusses how sarcopenia, age-related muscle loss, significantly impacts the ability of cancer patients to tolerate treatment, yet has historically not been considered very relevant. ImpediMed has developed an FDA-cleared digital health...


Oct 28, 2026

Dr. Aneel Nimba, Medical Director at Faron Pharmaceuticals,  discusses the company's innovative approach to treating higher risk myelodysplastic syndromes, a group of rare blood cancers, with its lead drug candidate that targets the CLEVER-1 receptor which controls the tumor microenvironment. This first-in-class...


Oct 28, 2026

Dr. Aneel Nimba, Medical Director at Faron Pharmaceuticals,  discusses the company's innovative approach to treating higher risk myelodysplastic syndromes, a group of rare blood cancers, with its lead drug candidate that targets the CLEVER-1 receptor which controls the tumor microenvironment. This first-in-class...


Oct 7, 2026

Dr. John Friend, CEO of Kazia Therapeutics, is investigating how to change the underlying biology that lets cancers resist treatment and evade the immune system. A central challenge in oncology is that cancer cells adapt and suppress immune recognition. Reprogramming the biology includes altering immune evasion...